Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum Electronic supplementary material The online version of this article (sunscreen with high ultraviolet (UV) A and UVB
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, irreversible and ultimately fatal chronic lung disease. Studies in Europe suggest that prevalence ranges from 1 to 23 cases per 100,000 persons [1] [2] [3] [4] [5] [6] . Prevalence and incidence rates increase with age, are higher among males and appear to be on the increase in recent years [7] . Prognosis is poor, with a median survival time of 2-5 years [8] [9] [10] [11] [12] .
Pirfenidone is currently the only approved drug for the treatment of adult patients with mild to moderate IPF [13] . It is licensed for use in the European Union and Canada (under the trade name Esbriet Ò , InterMune UK Ltd., London, UK) and in Japan, India, South Korea, and China. Data from Phase III, randomized, double-blind, placebo-controlled trials demonstrate that pirfenidone reduces the decline in lung function and improves progression-free survival time [14, 15] . In these studies, treatment with pirfenidone was safe and generally well tolerated; the most commonly reported treatment-emergent adverse events (AEs) were gastrointestinal (GI) and skin-related. These were generally mild to moderate in severity and rarely resulted in 
OVERVIEW OF PIRFENIDONE
Pirfenidone is an orally active, synthetic small molecule that inhibits the synthesis of transforming growth factor-b and tumor necrosis factor-a in preclinical models, both of which are cytokines known to play an active role in fibrosis and inflammation [16] [17] [18] [19] [20] [21] . Following oral administration with food to improve tolerability, pirfenidone is slowly absorbed and reaches peak concentrations after approximately 4 h [22] . The mean apparent terminal elimination half-life is approximately 2.4 h [23] .
Efficacy Profile
The clinical efficacy and safety of pirfenidone has been evaluated in four randomized, [14, 15, 24] . Data from the three Phase III, randomized, double-blind, placebo-controlled studies demonstrate that pirfenidone reduces the decline in lung function and improves progression-free survival [14, 15] . The two Phase III CAPACITY studies of pirfenidone in patients with IPF were designed similarly in order to enable pooling of data [25] . Analyses of pooled data from both trials enabled precise estimates of the magnitude of the treatment effect [25] . Results from the pooled analysis of categorical FVC change showed that pirfenidone reduced the proportion of patients experiencing at least a 10% decline by 30% compared with placebo [15] .
Additionally, numerically fewer overall deaths occurred in the pirfenidone versus placebo group [19 (6%) vs. 29 (8%); P = 0.141]. Significant and clinically meaningful treatment effects were observed across multiple outcomes in the CAPACITY studies ( Fig. 1a ) [26] . At Week 72, pirfenidone also reduced the proportion of patients with a 50 m or greater decrement in 6-min walk distance (31% relative reduction vs. placebo) and reduced the risk of death or disease progression (26% reduction vs. placebo, P = 0.025) [15] .
Safety Profile
The clinical safety profile of pirfenidone in patients with IPF has been demonstrated in large randomized, double-blind, placebo-controlled trials [14, 15, 24] , as well as in an ongoing long-term open-label extension trial [RECAP (Clinicaltrials.gov #NCT00662038)].
Pirfenidone's safety profile has been evaluated in a well-defined cohort of 789 patients exposed to treatment for up to 8 years (long-term safety pooling) [27] . In the CAPACITY studies, treatment with pirfenidone was generally well tolerated. Treatment discontinuation due to AEs was more common among pirfenidone 2,403 mg/day patients (15%) compared with placebo patients (9%); relative risk of 1.85 (95% CI 1.28-2.67, P = 0.001) [15, 28] .
Based on observations from the Japanese trials [14, 24] , proactive protocol-defined strategies including dose modification guidelines were implemented in the CAPACITY studies to minimize the incidence and severity of selected AEs (such as GI and skin-related AEs) and encourage patients to continue treatment. The most common AE leading to treatment discontinuation in both groups in the CAPACITY studies was IPF (3% in each group).
Other AEs leading to treatment discontinuation in at least 1% of pirfenidone-treated patients were rash and nausea.
The relatively low incidence of treatment discontinuation due to GI and skin-related AEs in the CAPACITY studies, compared with the Japanese studies, supports the use of protocol-defined strategies for proactively managing these events. However, GI and skin-related AEs remained the most commonly reported AEs in the CAPACITY studies. Gastrointestinal events of nausea, diarrhea, dyspepsia and vomiting were reported in 36%, 29%, 19% and 14% of pirfenidone-treated patients versus 17%, 19%, 7%, and 4% of placebo-treated patients, respectively [15] (InterMune data on file).
Skin-related AEs of rash and photosensitivity were reported in 32% and 12% of pirfenidone-treated patients versus 12% and 2% of placebo-treated patients, respectively [15] . These events were generally mild to moderate in intensity, reversible, and with minimal clinical consequence ( Tables 1, 2 ).
Gastrointestinal and skin-related AEs led to treatment discontinuation in six (1.7%) and eight (2.3%) pirfenidone-treated patients, respectively. The long-term safety pooling including 789 patients showed that GI and skin-related AEs have a tendency to occur early in the course of treatment and decrease over time [27] .
Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of more than three times the upper limit of normal occurred more frequently in the pooled pirfenidone group than in the pooled placebo group [14/345 (4%) vs. 2/347 (\1%), respectively] in the CAPACITY studies [15] .
Rarely, these have been associated with concomitant elevations in bilirubin. Liver function tests (ALT, AST, and bilirubin) should be conducted prior to the initiation of treatment with pirfenidone, and subsequently at monthly intervals for the first 6 months and then every 3 months thereafter [23] .
Gastrointestinal Adverse Events
Gastrointestinal AEs occurred at higher frequencies in patients treated with pirfenidone 2,403 mg/day compared with placebo in the CAPACITY studies (Table 1) . Importantly, there were no GI-related treatment-emergent serious AEs or hospitalizations among patients treated with pirfenidone. Overall, five (1.4%) and one (0.3%) pirfenidone patients discontinued therapy due a Consistent magnitude of treatment effect with pirfenidone across multiple clinically meaningful outcomes in patients with IPF [15] . Bars represent the magnitude of treatment effect, reported as relative difference between the pirfenidone and placebo groups. *From the pooled analysis of the CAPACITY studies at 72 weeks. Progression-free survival was defined as time to confirmed C10% decline in percentage predicted FVC, C15% decline in percentage predicted DLco or death. Deaths were not adjudicated and studies were not powered to evaluate mortality. b The incidence of pirfenidone-related skin rashes in patients with IPF was higher in the early summer months of the CAPACITY studies 004 and 006. Adapted from European Medicine Agency. Pirfenidone CHMP assessment report [38] . c Pirfenidone absorbs light in the ultraviolet spectrum. Adapted from Seto et al. [30] . 6MWD 6-min walk distance, DLco carbon monoxide diffusing capacity, e molar absorptivity coefficient, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, k max wavelength of the most intense ultraviolet absorption, PBO placebo, PEY patient-exposed years, PFD pirfenidone, PFS progression-free survival, UV ultraviolet b Table 1 Gastrointestinal adverse events in the CAPACITY studies Gastrointestinal AEs were mostly transient in nature, although dyspepsia was present for a median duration of 168 days [15] . While GI-related AEs were generally mild to moderate and transient, the frequency of such events suggests the need for proactive management.
Animal studies have shown that pirfenidone reduces the rate of gastric emptying and small intestinal transit [29] . These effects in rats were ameliorated by co-administration of prokinetic agents.
Concomitant administration of mosapride at 3 and 10 mg/kg resulted in significant amelioration in the decrease in gastric emptying rate induced by 100 mg/kg pirfenidone, while 1 mg/kg mosapride or greater ameliorated the decreased small intestinal transit rate [29] . Furthermore, GI effects in animals were observed following subcutaneous injection, indicating that systemic exposure is required for pirfenidone's gastric motility effects (InterMune data on file). The effect of food on the pharmacokinetics of pirfenidone has previously been examined in healthy adult subjects. It was demonstrated that co-administration with food decreased the peak concentration of pirfenidone (area under the curve was unchanged), with data also suggesting that food intake reduces the risk of GI-related AEs, thereby improving overall tolerability [22] .
Skin Reactions
Skin-related AEs in the context of pirfenidone therapy can manifest as an erythematous (with/ without edema) or as a phototoxic burn-like skin rash, occurring on sun-exposed body areas.
This differs from an allergic type of eruption, which will usually affect all parts of the skin, including areas not exposed to sunlight. In the placebo-treated patients [15] . An example of photosensitivity on the exposed skin of a pirfenidone-treated patient is shown in Fig. 2a .
The seasonal variation in frequency of skin reactions in the CAPACITY studies suggests an association with high-intensity sunlight exposure (Fig. 1b) . Laboratory studies have suggested that the underlying mechanism of pirfenidone in photosensitivity reactions is likely to be phototoxic and related to the drug's ability to absorb both ultraviolet (UV) B and UVA (Fig. 1c) [30] . Absorption of UV light by pirfenidone in skin tissue could result in skin lesions due to the generation of reactive oxygen species and lipid peroxidation, as both occur in vitro at physiologically relevant concentrations [30] . Although no wavelength dependency studies have been conducted in humans, preclinical guinea pig findings support the hypothesis that pirfenidone-induced skin reactions are phototoxic, and therefore proportional to light exposure and drug concentration [31] . These animal studies also demonstrate that the use of a sunscreen with a high protection factor significantly reduces the severity of skin reactions. Whether the wavelength dependency extends into the visible region in man is yet unknown. The patient presented with erythema localized to the more photoexposed areas of the hands. He had previously followed advice regarding photoprotection. On the day in question, he used a broad-spectrum SPF50? sunscreen in the morning before sun exposure, but did not repeat the application. b Patient 2: moderate photosensitivity after 14 days pirfenidone treatment. The patient presented with erythema and peeling, mainly on the hands and face. Patient had omitted to apply sunscreen protection. c Patient 2: the same patient improved following 7 days of topical treatment (silver sulfadiazine), sunscreen protection, and pirfenidone dose reduction. The patients and treating physicians provided permission for the use of these images. SPF sun protection factor
RECOMMENDATIONS FOR THE PREVENTION AND MANAGEMENT OF PIRFENIDONE-RELATED AES
Treatment management should be deployed in centers with appropriate expertise and experience in the management of IPF. The recommended daily dose of pirfenidone in Europe for adult patients with IPF is three 267 mg capsules three times a day with food (preferably at the end rather than the beginning of the meal) for a total of 2,403 mg/day [23] . Upon initiating treatment, the dose is titrated over a 14-day period to the recommended daily dose of nine capsules (2,403 mg) per day: first week, one capsule (267 mg) three times a day; second week, two capsules (534 mg) three times a day; third week onwards, full dose of three capsules (801 mg) three times a day [23] . It is recommended that pirfenidone is taken with food, typically during or after a meal in order to prevent drug-related AEs [23] . Generally, a stepwise clinical approach as described in Fig. 3 can be adopted to manage pirfenidone-related GI and skin-related AEs.
The following sections report recommendations on additional measures that may be adopted in daily practice for the prevention and management of GI and 
Gastrointestinal Adverse Events
In addition to current recommendations to take pirfenidone during or after a meal [23] , we suggest further practical considerations in patients experiencing tolerability challenges from GI AEs, such as taking each of the three capsules separately throughout the meal, rather than simultaneously. If the meal consists of several courses, each capsule could be taken between courses. In support for this recommendation, preclinical studies have shown that splitting pirfenidone doses partially alleviates pirfenidone's inhibitory effect on gastric motility in animal models (InterMune data on file). This is further supported by a real-world study in which patients were encouraged to take pirfenidone at the start, middle, and end of a meal to help minimize side-effects [32] .
To further improve pirfenidone's tolerability, we suggest that a longer initial dosing titration scheme-for example, starting with one capsule three times a day and titrating up to the full dose (three capsules three times a day) over a period of 4 weeks instead of 2 weeks-may be Fig. 3 Stepwise approach to the prevention and management of pirfenidone-related AEs. AE adverse event employed. This approach is currently under investigation in a clinical setting (Clincialtrials.gov #NCT01933334) [33] .
Dose Reduction
If pirfenidone-related AEs are not tolerable, dose reductions may be helpful, as the incidence of GI and skin-related AEs with pirfenidone treatment appear to be dose dependent as shown in animal models [34] . Depending on the nature and severity of the AE, we suggest that the pirfenidone dose may be reduced to 1 or 2 capsules (267-534 mg), 2-3 times a day with food, with re-escalation to the recommended daily dose as tolerated. In support of this suggestion, preclinical studies have shown that pirfenidone reduces gastric emptying and small intestinal transit rates in a dose-dependent manner [29] .
If dose reduction is required, we suggest to first reduce the dose corresponding to the time of the day when AEs are the most pronounced. For example, if nausea is experienced in the morning, delaying or reducing the morning dose to one or two capsules, may help mitigate GI symptoms. Dietary and cultural habits should be taken into account when advising patients.
Temporary Dose Interruption and

Re-challenging
If AEs still persist despite dose reduction, temporary treatment discontinuation until symptoms become tolerable (typically 1-2 weeks) should be considered. Once symptoms have resolved or become tolerable, pirfenidone may be re-introduced. In some treatment centers, a slower re-escalation scheme (i.e., longer than the usual 2 weeks) after temporary treatment interruption has been employed.
Prokinetic Medication
Use of prokinetic agents such as domperidone, mosapride, and metoclopramide may help mitigate treatment-related GI AEs [35] . Indeed, animal studies have shown that prokinetic agents such as mosapride reduce pirfenidone's inhibitory effects on gastric emptying and intestinal transit rates [29] . Metoclopramide (for a maximum of 5 days) and domperidone (no restriction on length of use) are both dosed at 10 mg three times a day. Use of proton pump inhibitors may also be helpful for managing GI side-effects in pirfenidone-treated patients with IPF [36] .
Skin-Related Adverse Events
Preclinical studies have shown that pirfenidone-induced photosensitivity reactions reflect the drug's pharmacokinetic profile and are proportional to sunlight exposure, decreasing with the use of higher sun protection factor (SPF) sunscreens. Therefore, sun exposure should be avoided for a few hours following pirfenidone intake, to allow the drug's plasma concentration to decrease. Animal studies have suggested that the extent of phototoxicity is linked to pirfenidone's plasma concentration (InterMune data on file).
The standard approach for preventing and managing skin AEs as recommended in the SmPC [23] includes avoiding exposure to direct sunlight (including sunlamps), use of sunscreen active against both UVA and UVB, use of protective clothing, and avoidance of other medicinal products known to cause photosensitivity. We expand on this guidance by suggesting: behavioral avoidance of indirect (in addition to direct) sunlight, as well as intense artificial light sources (such as energy-saving fluorescent lamps); wearing of Table 3 Summary of recommendations for the prevention and management of pirfenidone-related AEs
General approaches to preventing and managing pirfenidone-related AEs
Pirfenidone administration and dose modifications Pirfenidone capsules (267 mg) should be taken individually, over the course of a meal: fine tuning should take into account cultural dietary habits
If nausea is experienced in the morning, the morning dose may be delayed or reduced A maximum of three capsules (801 mg) should be taken with the main meal of the day, while fewer [1 or 2 capsules (267-534 mg)] may be taken with lighter meals Upon treatment initiation, the up-titration scheme can be extended to 4 weeks until the daily recommended dose is reached Temporary treatment interruptions should be considered if symptoms do not resolve following dose reduction Following dose interruption, pirfenidone could be re-introduced with a slower re-escalation scheme to the full dose
All treatment-related decisions should be made following discussion with the patient and with the aim of balancing quality of life and efficacy benefits Additional measures to manage GI AEs Prokinetic agents may help mitigate GI AEs Additional measures to prevention and manage skin AEs Prevention of photosensitivity reactions Change behavior to avoid sun exposure:
•
Seek to avoid sun exposure as much as possible, especially at mid-day, in the late afternoon, and during seasonal high UV periods. Remember that the sun's UVA component can penetrate clouds, clothing, and car windows
• Avoid sun exposure for a few hours after the meal at which pirfenidone was administered Protect skin from the sun with appropriate clothing: use of wide-brimmed hats, sunglasses, long-sleeve shirts, and trousers is recommended, as are gloves for driving and outdoor activities Protect skin from the sun with sunscreen: frequent and thorough application of a broad-spectrum SPF50 sunscreen with both UVA and UVB protection is mandatory Management of skin rashes
In case of rashes, pirfenidone dose should be reduced. If rashes still persist after 7 days, pirfenidone therapy should be discontinued for 15 days and may be slowly re-introduced once symptoms have resolved If rashes are due to an allergic reaction, pirfenidone therapy should be permanently discontinued thick-weave clothing, use of a broad-brimmed hat, and, when necessary, gloves.
To further illustrate the above guidance of the SmPC, Table 3 details our expert   recommendations to prevent skin photosensitivity reactions, highlighting the importance of behavioral changes and protection through appropriate clothing and thorough sunscreen application.
Dose Reduction
In cases of mild to moderate photosensitivity reaction or rash (i.e., when the vast majority of burn is superficial-painful erythema and scaling may be present on exposed areas, but with no edema, exudation, or blistering) that does not spontaneously resolve, the dose may be reduced to one capsule (267 mg) three times a day for 7 days, or until symptom resolution.
Symptoms are considered to be resolved once the redness and scaling have disappeared.
Temporary Dose Interruption and
Re-challenging If a rash persists for more than 7 days despite pirfenidone dose reduction, therapy should be discontinued for approximately 15 days. Upon resolution, pirfenidone may be re-introduced and re-escalated to the recommended daily dose, or as tolerated, in the same manner as the initial regime, or using the slower re-escalation regime previously described (i.e., extended over 4 weeks as opposed to 2 weeks).
Patients
experiencing a severe photosensitivity event (erythema and edema with exudation, erosions, blistering, cracked or scarred skin, possible dehydration) of sun-exposed skin (i.e., a non-allergic reaction), should be instructed to seek medical advice on dose adjustments and temporary discontinuation, until the skin reaction normalizes. In our collective clinical Table 3 continued In cases of severe photosensitivity reactions, pirfenidone should be discontinued and replaced with prednisone 25 mg/day for 7-10 days. After disappearance of the skin reaction, pirfenidone may be re-introduced following a very slow re-escalation Education Patient (and spousal) education should be undertaken at several levels (physician, nurse, and pharmacist) and should be supported by existing educational materials (e.g., patient information leaflet) Physicians play a central role in patient education and in providing best advice by considering the patient's clinical history, potential outdoor occupations/ hobbies/sport, or possible concomitant treatment with other photosensitizing drugs AE adverse event, GI gastrointestinal, SPF sun protection factor, UV ultraviolet experience, use of topical treatments for burns (e.g., silver sulfadiazine or potent steroids) immediately after the appearance of skin lesions may help attenuate reactions and improve associated symptoms. An example of a patient with moderate sensitivity treated with topical emollients and a reduction in pirfenidone dose is shown in Fig. 2b, c The outcomes of efficient patient communication are highlighted in a real-world pirfenidone study of 40 patients with IPF [32] . During the first 6 months of this study six patients (15%) discontinued treatment due to AEs. In the latter 10 months, however, there were no discontinuations. The authors of this study [32] attribute this to a number of factors, including a monthly specialist nurse review (for the first 3 months of treatment) to assess and reinforce AE avoidance measures. Patients were also given a contact number and encouraged to speak with a specialist nurse if they experienced any AEs; this ensured that appropriate measures such as dose reduction, temporary discontinuation, and/or additional treatment of side-effects could be enforced without delay in order to rapidly alleviate AEs [32] . This real-world study suggests that simple patient education and communication measures can substantially increase treatment adherence and compliance, which enables patients with IPF to benefit from the decreased disease progression observed with continued pirfenidone treatment. version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
